Moonlake Immunotherapeutics (MLTX) Stock Price, Quote & News

Company Profile

MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerla...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 415108022

Website: www.moonlaketx.com

Address:

Dorfstrasse 29, Zug, Switzerland

MarkGoldw Aug. 24 at 2:44 PM

$MLTX Don't blame me. I warned the board when Jorge sold at 20. But the scammer with crew said, it was pre planed, what's fucx pre planed? These peole always knew their things. Inside selling also a big RED flag.

0 · Reply

jayjaynyc Aug. 24 at 2:04 PM

$MLTX Moved some from here to ALMS.

0 · Reply

pizzza Aug. 24 at 1:58 PM

$MLTX can't tell me this is retail dropping it. Faith in this is gone for now

0 · Reply

Modern_portholio_theory Aug. 24 at 1:41 PM

$MLTX only 1.6 million shares left to borrow to short, likely what caused price to drop last week expecting the rate to borrow will rise shorts need you to sell your shares so they can cover their positions

0 · Reply

perplex Aug. 24 at 1:40 PM

$MLTX Down 17% in 6M with two positive phase 3 trials… Hard for that to sink in, right?

1 · Reply

FlyingChemist01 Aug. 24 at 1:32 PM

$MLTX and way down we go 😂

0 · Reply

steadyhandswin Aug. 24 at 1:15 PM

$MLTX any time you want to gain some momentum is fine with us!!

0 · Reply

Obidagreat Aug. 24 at 12:20 PM

$MLTX

0 · Reply

Antocar Aug. 24 at 11:34 AM

$MLTX There is a risk of a drop below $15 in the near future. Furthermore, if Jorge were to execute the potential dilution plan of an additional $300 million, the price could drop to $11-12. Be careful

0 · Reply

Antocar Aug. 24 at 8:23 AM

$MLTX With another CEO, we'd already be at $50. But unfortunately, we have this trio...

0 · Reply

MoonLake price target raised to $50 from $45 at H.C. Wainwright

Aug 10, 2026, 8:07 AM EDT - 14 days ago

MoonLake's psoriatic arthritis drug meets key goals in late-stage trial

2026-08-10T11:45:28.000Z - 14 days ago

MoonLake Immunotherapeutics reports Q2 EPS (84c), consensus (90c)

2026-08-10T11:40:14.000Z - 14 days ago

MoonLake says Phase 3 IZAR-1 trial met all clinical endpoints at Week 16

Aug 10, 2026, 7:00 AM EDT - 14 days ago

MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results

Aug 10, 2026, 7:00 AM EDT - 14 days ago

MoonLake Immunotherapeutics Earnings release: Q2 2026

Aug 10, 2026, 7:00 AM EDT - 14 days ago

MoonLake Immunotherapeutics Quarterly report: Q2 2026

2026-06-24T10:25:15.000Z - 2 months ago

MoonLake Immunotherapeutics 9M share Secondary priced at $20.00

Jun 23, 2026, 11:08 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering

2026-06-22T20:17:49.000Z - 2 months ago

MoonLake Immunotherapeutics announces $150M offering of Class A ordinary shares

Jun 22, 2026, 4:01 PM EDT - 2 months ago

MoonLake Immunotherapeutics Announces Proposed Public Offering

2026-06-22T17:45:23.000Z - 2 months ago

MoonLake’s SLK has ‘blockbuster potential,’ says Clear Street

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Jun 22, 2026, 8:00 AM EDT - 2 months ago

MoonLake Immunotherapeutics Slides: FY 2026

2026-06-22T01:20:59.000Z - 2 months ago

MoonLake announces Week 52 results of Phase 3 VELA-1, VELA-2 trials

Jun 21, 2026, 5:00 PM EDT - 2 months ago

MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Earnings release: Q1 2026

May 11, 2026, 7:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Quarterly report: Q1 2026

2026-05-11T10:50:53.000Z - 3 months ago

MoonLake price target raised to $45 from $40 at H.C. Wainwright

2026-05-10T19:10:05.000Z - 3 months ago

MoonLake FDA meeting yields ‘best-in-class’ label, says Clear Street

2026-05-10T18:50:45.000Z - 3 months ago

MoonLake says aligned with FDA on submission plans for sonelokimab

2026-05-10T18:50:05.000Z - 3 months ago

MoonLake Immunotherapeutics reports Q1 EPS -98c vs. -91c last year

May 10, 2026, 9:00 AM EDT - 3 months ago

MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 4 months ago

MoonLake Immunotherapeutics Proxy statement: Proxy filing

2026-03-29T14:35:05.000Z - 5 months ago

MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial

Mar 28, 2026, 3:00 PM EDT - 5 months ago

MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting

2026-03-26T17:25:33.000Z - 5 months ago

MoonLake Immunotherapeutics management to meet with BTIG

2026-03-23T09:45:29.000Z - 5 months ago

MoonLake upgraded to Outperform from Underperform at Wolfe Research

2026-03-19T08:50:28.000Z - 5 months ago

MoonLake upgraded to Buy from Neutral at Rothschild & Co Redburn

2026-03-11T10:36:37.000Z - 5 months ago

MoonLake price target raised to $70 from $45 at Clear Street

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Transcript: Investor Day 2026

Feb 23, 2026, 8:00 AM EST - 6 months ago

MoonLake Immunotherapeutics Slides: FY 2026

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Annual report: Q4 2025

Feb 22, 2026, 4:00 PM EST - 6 months ago

MoonLake Immunotherapeutics Earnings release: Q4 2025

Feb 10, 2026, 7:00 AM EST - 6 months ago

ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

IMA

Feb 2, 2026, 8:00 AM EST - 7 months ago

MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day

Jan 27, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Closing of $172.5 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Jan 23, 2026, 7:30 AM EST - 7 months ago

Helix Acquisition Corp. III Announces Pricing of Upsized $150 Million Initial Public Offering

Dec 11, 2025, 8:54 AM EST - 9 months ago

DEADLINE NEXT WEEK: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Contact the Firm Before December 15, 2025

Dec 5, 2025, 8:18 AM EST - 9 months ago

MoonLake Immunotherapeutics (MLTX) Investors are Encouraged to Act before the Upcoming December 15 Securities Fraud Deadline – Contact BFA Law if You Lost Money

Dec 3, 2025, 7:46 AM EST - 9 months ago

MLTX NEWS: MoonLake Immunotherapeutics Sued for Securities Fraud after Stock Plummets 90% -- Investors Notified to Contact BFA Law by December 15 Deadline

Dec 1, 2025, 3:18 PM EST - 9 months ago

MLTX SHAREHOLDERS: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15

Nov 30, 2025, 7:45 AM EST - 9 months ago

MLTX LAWSUIT: BFA Law Reminds MoonLake Immunotherapeutics Investors the Company has been Sued for Securities Fraud and to Contact BFA Law by December 15 Deadline

Nov 24, 2025, 6:08 AM EST - 9 months ago

MOONLAKE NOTICE: MoonLake Immunotherapeutics (MLTX) Faces Securities Fraud Allegations after Stock Drops 90%, Investors Urged to Contact BFA Law

Nov 14, 2025, 6:08 AM EST - 10 months ago

MOONLAKE INVESTORS: MoonLake Immunotherapeutics (MLTX) has been Sued for Securities Fraud, Investors are Urged to Contact BFA Law

Nov 10, 2025, 8:15 AM EST - 10 months ago

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) DEADLINE ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

Nov 10, 2025, 6:06 AM EST - 10 months ago

MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Earnings release: Q3 2025

Nov 5, 2025, 4:00 PM EST - 10 months ago

MoonLake Immunotherapeutics Quarterly report: Q3 2025

Nov 5, 2025, 7:11 AM EST - 10 months ago

MoonLake Immunotherapeutics Announces Pricing of $75 Million Underwritten Offering

Nov 5, 2025, 7:00 AM EST - 10 months ago

MoonLake Immunotherapeutics Reports Third Quarter 2025 Financial Results and Announces New Data from Clinical Trials of its Nanobody® Sonelokimab

Nov 1, 2025, 7:08 AM EDT - 10 months ago

MLTX INVESTOR REMINDER: MoonLake Immunotherapeutics Investors may have been Affected by Fraud -- Contact BFA Law if You Suffered Losses

MarkGoldw Aug. 24 at 2:44 PM

0 · Reply

jayjaynyc Aug. 24 at 2:04 PM

$MLTX Moved some from here to ALMS.

0 · Reply

pizzza Aug. 24 at 1:58 PM

$MLTX can't tell me this is retail dropping it. Faith in this is gone for now

0 · Reply

Modern_portholio_theory Aug. 24 at 1:41 PM

0 · Reply

perplex Aug. 24 at 1:40 PM

$MLTX Down 17% in 6M with two positive phase 3 trials… Hard for that to sink in, right?

1 · Reply

FlyingChemist01 Aug. 24 at 1:32 PM

$MLTX and way down we go 😂

0 · Reply

steadyhandswin Aug. 24 at 1:15 PM

$MLTX any time you want to gain some momentum is fine with us!!

0 · Reply

Obidagreat Aug. 24 at 12:20 PM

$MLTX

0 · Reply

Antocar Aug. 24 at 11:34 AM

0 · Reply

Antocar Aug. 24 at 8:23 AM

$MLTX With another CEO, we'd already be at $50. But unfortunately, we have this trio...

0 · Reply

BuzzBeatz1945 Aug. 24 at 2:25 AM

$MLTX @BioRich What are your thoughts on MLTX short and long term? Likely for BO? HS is a shoe in with other potential catalysts. Current SP is down due to terrible management..

2 · Reply

cranberry1 Aug. 23 at 11:33 PM

$MLTX when you least expect it

0 · Reply

timetravelBob Aug. 23 at 11:03 PM

$MLTX funny how this is nothing trending this sunday lol

1 · Reply

Modern_portholio_theory Aug. 23 at 10:42 PM

$MLTX likely an unpopular opinion, however it is a natural reaction to want someone to blame when the stock price goes down, this was always going to have volatility and regardless of whether it is just paper gains or losses, the losses tend to hurt more than the gains if you want to see a disaster in management, look at avxl; our situation just requires patience and ive accepted the three main members of mltx will continue to be rewarded with handsome stock awards regardless of the stock price… in also sure they are busy assembling the bla package

0 · Reply

CknSalad Aug. 23 at 9:23 PM

$MLTX Still holding until end of year or early next year. Pretty annoyed at management. Honestly would be more than happy with 5-6B BO at this point.

0 · Reply

ron79 Aug. 23 at 5:42 PM

$MLTX I am hoping Jorge is playing chess and has a buyer interest not only in the drug, but also the cash on hand. Consider this, with $537M on hand, MLTX has the equivalent of 7% of Novartis reserves and almost 10% of Sanofi's cash on hand. These are not small number. The ability to be acquired and be a drain on cash should be hugely appealing.

4 · Reply

cranberry1 Aug. 23 at 4:41 PM

$MLTX 64

0 · Reply

Obidagreat Aug. 23 at 2:41 PM

$MLTX

0 · Reply

USAEquityResearch Aug. 23 at 9:12 AM

$MLTX 📊 USAEquityResearch ▼ 15.76 (-0.69%) Trend: Bearish 📉 RSI (14): 36.8 — weak momentum, approaching oversold MACD: bearish, below signal line Volume: normal 📌 Key Levels Resistance: 19.88 | Support: 15.76 20-MA: 17.44 | 50-MA: 18.70 💼 Fundamentals Mkt Cap: $1.34B FCF: $-131.86M (-1.55/sh) Total Debt: $101.53M D/E: 23.71 📉 Options (exp 2026-09-18) ATM IV: 78.2% | Skew: +10.4% (put-heavy) P/C Ratio: 0.27 🐂 Bullish lean Max Pain: 18.00 Call wall: 17.00 | Put wall: 15.00 Educational content only. Not financial advice. Full data, options chain & financials: https://usaequityresearch.com/stocks/MLTX

0 · Reply

kogklasse Aug. 23 at 8:46 AM

$MLTX Management have shit load of shares. They want to get their money at some point. And they will. They fucked up real hard not saying shit about the offering after 52 week HS data and then dropping somewhat slight under expectation PsA data. While NOT hosting s webinar. Damn they know they would be roasted. MLTX time will come. I do not think it will happen before 2027.

2 · Reply

fortnyce Aug. 23 at 5:41 AM

$MLTX are you worried that a market crash (>50%) screws our MLTX investment?

0 · Reply

Modern_portholio_theory Aug. 23 at 12:32 AM

$MLTX anyone find it interesting that our favourite analyst at rbc has slowing increased their price prediction from ten dollars last september to seventeen dollars now, maintaining a hold

1 · Reply

Market Cap	1.34B
Revenue (ttm)	0.00
Net Income (ttm)	-227.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.23

Volume	1,351,500
Avg Vol	1,347,766
Day's Range	N/A - N/A
Shares Out	85.11M
Stochastic %K	10%
Beta	1.06
Analysts	Strong Sell
Price Target	$33.38